Nextbiotixis developing microbiome-based therapies using single microbial strains that interact with human cells in the gut. Acting more effectively on immunomodulatory pathways, they are intended to treat patients suffering from inflammatory bowel diseases. Read morehere
Researchersexamined the oral and gut microbiome of melanoma patients undergoing anti–programmed cell death 1 protein (PD-1) immunotherapy (n= 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n= 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P< 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P< 0.01) in responding patients.